Description

Sotrovimab

Sotrovimab is a monoclonal antibody created to help treat COVID-19. It specifically targets the SARS-CoV-2 spike protein, thereby aiding the immune system in identifying and combating the virus. Sotrovimab captured interest during the COVID-19 pandemic as an antibody therapy designed for individuals at high risk of developing severe disease.

Nonetheless, viruses do evolve, and consequently, medical advice and product availability can change. It is essential for individuals to verify the latest guidance prior to contemplating any Covid-19 medication.

Sotrovimab is a monoclonal antibody that has been developed for the treatment of COVID-19. It is designed to target the virus and help the immune system fight off the infection.

Sotrovimab is a synthetic protein designed to replicate an immune response. Monoclonal antibodies are specifically engineered to target particular molecules on viruses or other substances in the body. In contrast, regular tablets enter the body through the digestive system.

Sotrovimab was marketed as Xevudy. Initially, it received approval in the European Union for adults and adolescents aged 12 years and older, provided they weighed at least 40 kg (88 pounds), had COVID-19, did not require supplemental oxygen, and were at an increased risk of progressing to severe disease.

Sotrovimab works by targeting the spike protein of the SARS-CoV-2 virus, thereby preventing it from entering human cells. This mechanism helps to neutralise the virus and reduce the severity of the infection.

Sotrovimab attaches to a specific region of the SARS-CoV-2 spike protein. Consequently, it was intended to disrupt the virus’s capacity to penetrate human cells.

As SARS-CoV-2 continues to evolve, it is important to note that the efficacy of antibody therapeutics may vary based on the circulating variants of the virus. Consequently, health authorities have been consistently assessing monoclonal antibody treatments as new variants emerge.

Sotrovimab was used due to its effectiveness in treating certain viral infections. Additionally, it was considered for its potential to reduce the severity of symptoms and improve patient outcomes.

Sotrovimab was developed to treat specific individuals with mild to moderate COVID-19, particularly those at an increased risk of progressing to severe COVID-19. It should be noted that this is not a replacement for vaccination or other preventive measures.

It is important to note that it was generally used for specific medical conditions, rather than being a routine treatment for all patients with COVID-19. The clinical decision as to whether antibody treatment was indicated was made by a health care professional based on the patient’s condition and the guidance available at the time.

Sotrovimab Administration

Sotrovimab was given by a healthcare professional, not as a standard home-use tablet. The drug was administered by intravenous infusion under the supervision of medical personnel.

Infusion medicines can cause reactions and appropriate monitoring was important during and post infusion.

Potential Side Effects

Like other medicines, Sotrovimab can cause unwanted effects. Concerns reported included infusion-related reactions and hypersensitivity reactions. Some people might also have symptoms such as nausea, headache, dizziness or other short-term effects.

Severe allergic reactions require emergency medical treatment. Signs may include trouble breathing, swelling of the face or throat, a bad rash, or sudden weakness.

Patients should report any unexpected or severe symptoms to a healthcare professional immediately.

Current Status Important

The regulatory status of sotrovimab has changed since its was introduced. The European Medicines Agency reports that the marketing authorisation holder has requested the permanent withdrawal of the marketing authorisation for commercial reasons. On 18 February 2026, the European Commission withdrew the marketing authorisation.

Also, COVID-19 treatment recommendations are periodically reviewed as evidence, circulating variants, and available medicines change. The World Health Organisation has a living guideline on COVID-19 therapeutics.

Therefore, historical information on sotrovimab should not be assumed to be current treatment advice.

FAQs on Sotrovimab

What does sotrovimab treat?

Sotrovimab was developed as a monoclonal antibody therapy for some COVID-19 patients at increased risk of severe disease.

Is sotrovimab an anti-biotic?

“No. Sotrovimab is a monoclonal antibody and is not an antibiotic. Antibiotics are used against bacteria, whereas sotrovimab was developed to target SARS-CoV-2.

Is Sotrovimab a vaccine?

“No. Sotrovimab is not a vaccine. It was designed to treat certain COVID-19 patients and not for regular vaccinations.

Sotrovimab was given intravenously.

Sotrovimab was administered via intravenous infusion under professional medical supervision.

Is old information about Sotrovimab still applicable for the treatment of COVID-19 today?

You should not take any medication based on old information alone. Treatments for COVID-19 are continually changing. Check with your health care professional for the latest recommendations.

Conclusion

Sotrovimab was an important step in the development of antibody-based therapies for COVID-19. It was designed to target the spike protein of SARS-CoV-2 and was used for selected high-risk patients during the period of its authorisation.